Cannabidiol and Older Adult Cannabis Users
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Sleep, Anxiety, Depression, Pain
In brief
Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo. This work has the ability to directly inform individual choices regarding the use of cannabis products among older adults, and direct policy decisions regulating cannabis formulations on the legal market.
Key facts
- Study ID
- NCT06290063
- Run by
- University of Colorado, Boulder
- People needed
- 385
- Starts
- 2024-05-01
- Expected to finish
- 2028-08-31
- Last updated by the study team
- 2026-06-10
Who can join
Age: 60 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- At least 60 years of age
- Able to provide informed consent
- Must have used a cannabis product at least once with no negative effects
- Must not have been regularly using any cannabis products (<3x/month) in the last 6 months
- Female participants must be postmenopausal
- Liver function tests (Alanine transaminase (ALT) and
- Aspartate transaminase (AST)) must show levels no greater than 2x the upper normal limits for age
- Must be currently taking medication/s for pain, sleep, and/or mood
You may not qualify if…
- Blood alcohol level > 0 at screening (to sign consent form)
- Report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs
- Past or current diagnosis, or family history of diagnosis of psychosis
- Current use of anti-epileptic medications (e.g. clobazam, sodium valproate)
- Current use of medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and/or teriflunomide).
- Current use of antipsychotic medications
- Currently undergoing chemotherapy (to prevent drug interactions)
Where it is running
- University of Colorado at Boulder — Boulder, Colorado, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.